Literature DB >> 15505154

1H MR spectroscopy in common dementias.

K Kantarci1, R C Petersen, B F Boeve, D S Knopman, D F Tang-Wai, P C O'Brien, S D Weigand, S D Edland, G E Smith, R J Ivnik, T J Ferman, E G Tangalos, C R Jack.   

Abstract

OBJECTIVE: To determine the 1H MR spectroscopic (MRS) findings and intergroup differences among common dementias: Alzheimer disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal lobar degeneration (FTLD).
METHODS: The authors consecutively recruited 206 normal elderly subjects and 121 patients with AD, 41 with FTLD, 20 with DLB, and 8 with VaD. The 1H MRS metabolite ratio changes in common dementias were evaluated with respect to normal and also differences among the common dementias.
RESULTS: N-acetylaspartate (NAA)/creatine (Cr) was lower than normal in patients with AD, FTLD, and VaD. Myo-inositol (mI)/Cr was higher than normal in patients with AD and FTLD. Choline (Cho)/Cr was higher than normal in patients with AD, FTLD, and DLB. There were no metabolite differences between patients with AD and FTLD or between patients with DLB and VaD. NAA/Cr was lower in patients with AD and FTLD than DLB. MI/Cr was higher in patients with AD and FTLD than VaD. MI/Cr was also higher in patients with FTLD than DLB.
CONCLUSIONS: NAA/Cr levels are decreased in dementias that are characterized by neuron loss, such as AD, FTLD, and VaD. MI/Cr levels are elevated in dementias that are pathologically characterized by gliosis, such as AD and FTLD. Cho/Cr levels are elevated in dementias that are characterized by a profound cholinergic deficit, such as AD and DLB.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505154      PMCID: PMC2766798          DOI: 10.1212/01.wnl.0000141849.21256.ac

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  36 in total

1.  Assessment of 3D proton MR echo-planar spectroscopic imaging using automated spectral analysis.

Authors:  A Ebel; B J Soher; A A Maudsley
Journal:  Magn Reson Med       Date:  2001-12       Impact factor: 4.668

2.  Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people.

Authors:  Adam D B Waldman; Gurcharan S Rai; James R McConnell; Mahera Chaudry; David Grant
Journal:  Arch Gerontol Geriatr       Date:  2002 Sep-Oct       Impact factor: 3.250

3.  N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study.

Authors:  W E Klunk; K Panchalingam; J Moossy; R J McClure; J W Pettegrew
Journal:  Neurology       Date:  1992-08       Impact factor: 9.910

4.  Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.

Authors:  A Satlin; N Bodick; W W Offen; P F Renshaw
Journal:  Am J Psychiatry       Date:  1997-10       Impact factor: 18.112

5.  Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia.

Authors:  V J Kattapong; W M Brooks; M H Wesley; P W Kodituwakku; G A Rosenberg
Journal:  Arch Neurol       Date:  1996-07

6.  Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry.

Authors:  E J Burton; G Karas; S M Paling; R Barber; E D Williams; C G Ballard; I G McKeith; P Scheltens; F Barkhof; J T O'Brien
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

7.  Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series.

Authors:  A Lim; D Tsuang; W Kukull; D Nochlin; J Leverenz; W McCormick; J Bowen; L Teri; J Thompson; E R Peskind; M Raskind; E B Larson
Journal:  J Am Geriatr Soc       Date:  1999-05       Impact factor: 5.562

8.  Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.

Authors:  K Ranga Rama Krishnan; H Cecil Charles; P Murali Doraiswamy; Jacobo Mintzer; Richard Weisler; Xin Yu; Carlos Perdomo; John R Ieni; Sharon Rogers
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

9.  Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease.

Authors:  Pietro Tiraboschi; Larry A Hansen; Michael Alford; Annette Merdes; Eliezer Masliah; Leon J Thal; Jody Corey-Bloom
Journal:  Arch Gen Psychiatry       Date:  2002-10

10.  Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging.

Authors:  S MacKay; D J Meyerhoff; J M Constans; D Norman; G Fein; M W Weiner
Journal:  Arch Neurol       Date:  1996-02
View more
  81 in total

1.  [MR spectroscopy in dementia].

Authors:  T Hauser; L Gerigk; F Giesel; L Schuster; M Essig
Journal:  Radiologe       Date:  2010-09       Impact factor: 0.635

2.  Proton MR spectroscopy and white matter hyperintensities in idiopathic normal pressure hydrocephalus and other dementias.

Authors:  O Algin; B Hakyemez; M Parlak
Journal:  Br J Radiol       Date:  2010-07-20       Impact factor: 3.039

3.  Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.

Authors:  Pedro J Modrego; Miguel A Pina; Nicolás Fayed; Marcos Díaz
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy.

Authors:  Akihiko Shiino; Toshiyuki Watanabe; Yoshitomo Shirakashi; Emi Kotani; Masahiro Yoshimura; Shigehiro Morikawa; Toshiro Inubushi; Ichiro Akiguchi
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-08       Impact factor: 6.200

5.  Imaging correlates of posterior cortical atrophy.

Authors:  Jennifer L Whitwell; Clifford R Jack; Kejal Kantarci; Stephen D Weigand; Bradley F Boeve; David S Knopman; Daniel A Drubach; David F Tang-Wai; Ronald C Petersen; Keith A Josephs
Journal:  Neurobiol Aging       Date:  2006-06-23       Impact factor: 4.673

Review 6.  Alzheimer's disease and mild cognitive impairment.

Authors:  Brendan J Kelley; Ronald C Petersen
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

Review 7.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

8.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

9.  Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements.

Authors:  Kejal Kantarci; David S Knopman; Dennis W Dickson; Joseph E Parisi; Jennifer L Whitwell; Stephen D Weigand; Keith A Josephs; Bradley F Boeve; Ronald C Petersen; Clifford R Jack
Journal:  Radiology       Date:  2008-07       Impact factor: 11.105

10.  Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies.

Authors:  Jonathan Graff-Radford; Bradley F Boeve; Melissa E Murray; Tanis J Ferman; Nirubol Tosakulwong; Timothy G Lesnick; Mandie Maroney-Smith; Matthew L Senjem; Jeffrey Gunter; Glenn E Smith; David S Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Kejal Kantarci
Journal:  Neurobiol Aging       Date:  2014-01-08       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.